Get all premium features to the best stock analysis tool

RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment

TIGeR-PaC Trial Enrollment Remains on Track for Completion in First Half of 2026, with Final Data Expected in 2027 Select TIGeR-PaC Cancer Centers Now Using RenovoCath ® as a Stand-Alone Device for Drug-Delivery in Oncology Management MOUNTAIN VIEW, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ® , a patented, FDA-cleared drug-delivery device, today announced the Company has achieved a key milestone in its ongoing Phase III TIGeR‑PaC clinical trial by surpassing 100 randomized patients and remains on track for enrollment completion in the first half of 2026, with final data expected in 2027.

RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement

Company has the funding, business plan, leadership and infrastructure to propel achievement of upcoming commercial and clinical milestones Company has the funding, business plan, leadership and infrastructure to propel achievement of upcoming commercial and clinical milestones

RenovoRx Announces $10 Million at Market Private Placement

Bolstered Cash Position Expected to Capitalize the Company's Momentum Towards Important Milestones, Including Breakeven Operations and Trial Data

RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum

Over the past year, RenovoRx has Tripled Commercially Active U.S. Cancer Centers and Centers Requesting Access to RenovoCath, its FDA-Cleared Device